SCHEMBL2647403

SCHEMBL2647403

O=C(C=Cc1cccc(OC(F)(F)F)c1)c1ccc(C2CCCCC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.53
NPC1 O15118 1/20 0.53
POLB P06746 1/20 0.53
RAB9A P51151 1/20 0.53
BLM P54132 1/20 0.53
KMT2A Q03164 1/20 0.53
GPR35 Q9HC97 1/20 0.53
MAOB P27338 4/20 0.49
P4HB P07237 3/20 0.47
BCHE P06276 3/20 0.46
CYP1A1 P04798 2/20 0.44
CYP1B1 Q16678 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
NR1H4 Q96RI1 2/20 0.43
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
TAS1R2 Q8TE23 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2664949 0.89 NPC1 (0.53) MEN1NPC1POLBRAB9ABLM
SCHEMBL2647408 0.89 NPC1 (0.53) MEN1NPC1POLBRAB9ABLM
SCHEMBL2664946 0.86 NPC1 (0.67) MEN1NPC1POLBRAB9ABLM
SCHEMBL2647346 0.86 NPC1 (0.67) MEN1NPC1POLBRAB9ABLM
SCHEMBL2647347 0.86 NPC1 (0.67) MEN1NPC1POLBRAB9ABLM
SCHEMBL9071393 0.85 NPC1 (0.65) MEN1NPC1POLBRAB9ABLM
SCHEMBL2647451 0.85 NPC1 (0.65) MEN1NPC1POLBRAB9ABLM
SCHEMBL2647449 0.85 NPC1 (0.65) MEN1NPC1POLBRAB9ABLM
SCHEMBL2646518 0.84 MAOB (0.64) MEN1KMT2AMAOBP4HBBCHE
SCHEMBL25198625 0.83 NPC1 (0.58) MEN1NPC1POLBRAB9ABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1463715-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-10-06 EP disclosed
US-6762318-B2 CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION NOVO NORDISK A/S (DK) 2004-07-13 US disclosed
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents PFIZER INC 2003-12-25 US disclosed
WO-2003048109-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents GPR119, GLP1R, GIPR MEN1 2548/4885NPC1 1374/4885POLB 4789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.